A-
Overall grade
B+
Financial quality
The sleeper story is Natera's stealth path to doubling revenue per test - they're processing ~1 million 22q tests annually at zero reimbursement, all built into current COGS, waiting for ACOG guidelines to flip the switch. The obvious headline is record Signatera growth, but the real story is 45% of US oncologists are already ordering - this isn't about new customer acquisition, it's about existing users expanding utilization on more patients. The binding constraint is implementation capacity (EMR integration, mobile phlebotomy infrastructure), not demand or competition. Steve's most revealing quote: 'Revenue growth is going to be accelerating above the level of volume growth' because they're building coverage for tests they already process. My view changes if commercial payer wins don't accelerate by Q3 despite the biomarker state policy publications.
The 30-second version
- Signatera ASPs hit $1,100 but revenue-per-test could double to $2,000 - the real story is the stealth path to commercial payer coverage
- Record 16,500 Signatera sequential unit growth (best ever) but the binding constraint is implementation capacity, not demand
- Women's Health +40,000 sequential units despite no major product launches - the microdeletion opportunity is hiding in plain sight
What changed this quarter
| Metric | Prior | This quarter |
|---|---|---|
| Total Revenue | $476M (Q4 2024, +53% YoY) | $502M (Q1 2025, +37% YoY) |
| Total Volume | ~785K units (Q4 2024) | 855K units (Q1 2025, +26% YoY) |
| Signatera Clinical Units | ~154K units (Q4 2024) | ~170.5K units (Q1 2025, +52% YoY) |
| Signatera ASP | ~$1,100 (Q4 2024) | >$1,100 (Q1 2025) |
| Women's Health Volume | ~580K units (Q4 2024) | ~620K units (Q1 2025) |
| Organ Health Growth | Strong growth (Q4 2024) | >50% YoY growth (Q1 2025) |
| Gross Margin | 63% including true-ups (Q4 2024) | 63% including $34M true-ups (Q1 2025) |
| Cash Generation | $46M (Q4 2024) | $23M (Q1 2025) |
Accountability tracked
8 new promises made4 narrative shifts flagged6 prior promises graded
Inside the full report
The complete write-up covers the full promise ledger with kept/missed calls, disclosure-quality scoring, the metrics-vanished check, verification items, and the questions to ask next quarter.
Subscribe to Call Sheet Daily →